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Introduction: The novel arthritis-specific Work Productivity Survey (WPS) was developed to estimate patient
productivity limitations associated with arthritis within and outside the home, which is an unmet need in psoriatic
arthritis (PsA). The WPS has been validated in rheumatoid arthritis. This report assesses the discriminant validity,
responsiveness and reliability of the WPS in adult-onset PsA.
Methods: Psychometric properties were assessed using data from the RAPID-PsA trial (NCT01087788) investigating
certolizumab pegol (CZP) efficacy and safety in PsA. WPS was completed at baseline and every 4 weeks until Week
24. Validity was evaluated at baseline via known-groups defined using first and third quartiles of patients’ Disease
Activity Score 28 based on C-reactive protein (DAS28(CRP)), Health Assessment Questionnaire-Disability Index
(HAQ-DI), Short Form-36 (SF-36) items and PsA Quality of Life (PsAQoL) scores. Responsiveness and reliability were
assessed by comparing WPS mean changes at Week 12 in American College of Rheumatology 20% improvement
criteria (ACR20) or HAQ-DI Minimal Clinically Important Difference (MCID) 0.3 responders versus non-responders, as
well as using standardized response means (SRM). All comparisons were conducted on the observed cases in the
Randomized Set, regardless of the randomization group, using a non-parametric bootstrap-t method.
Results: Compared with patients with a better health state, patients with a worse health state had on average 2 to
6 times more household work days lost, more days with reduced household productivity, more days missed of
family/social/leisure activities, more days with outside help hired and a significantly higher interference of arthritis
per month. Among employed patients, those with a worse health state had 2 to 4 times more workplace days lost,
more days with patient workplace productivity reduced, and a significantly higher interference of arthritis on patient
workplace productivity versus patients with a better health state. WPS was also responsive to clinical changes, with
responders having significantly larger improvements at Week 12 in WPS scores versus non-responders. The effect sizes
for changes in productivity in ACR20 or HAQ-DI MCID responders were moderate (0.5 < SRM < 0.8) or small.
Conclusions: These analyses demonstrate the validity, responsiveness and reliability of the WPS, as an instrument for
the measurement of patient productivity within and outside the home in an adult-onset PsA population.* Correspondence: jtosterhaus@mindspring.com
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Psoriatic arthritis (PsA) is an inflammatory arthritis that
occurs in up to one-third of patients with psoriasis. In
about 80% of PsA cases, the arthritis develops after the ap-
pearance of psoriasis [1]. The risk of a patient with psoria-
sis developing arthritis is greater in individuals with severe
psoriasis, yet occasionally severe arthritis may occur with
minimal skin disease.
While there is published evidence for the burden of the
disease on work disability and the validity of different
measurement tools in related rheumatic diseases such as
rheumatoid arthritis (RA) and ankylosing spondylitis [2],
to date there are limited data on work disability in PsA
[3,4]. Some evidence indicates that the employment rate
in patients with PsA is significantly lower than that seen in
the general population and is slightly lower than in the an-
kylosing spondylitis population, but is higher than in the
RA population [5].
In contrast to RA, very little is known about the indirect
costs associated with PsA and its treatment. Only three
published studies assessing indirect monetary costs associ-
ated with PsA investigated the cost of presenteeism, which
is expected to be one of the larger components of the in-
direct costs of PsA. One study only assessed indirect costs
in terms of costs due to short-term absence from work
and permanent work disability [6]. The remaining two
studies only assessed indirect costs in terms of costs due
to short-term absence [7,8]; the second of these studies in-
cluded costs due to both caregivers’ and patients’ short-
term absences from work [8].
The lack of information describing the indirect costs of
PsA does not reflect its impact on society. The age of on-
set of PsA is generally between 30 and 50 years [9,10], with
the mean age of diagnosis estimated at 41 to 44 years of
age [9,11], at which stage many men and women are in
the midst of their working careers. Additionally, two sep-
arate studies to identify issues of concern amongst PsA pa-
tients reported that reduced ability to work or volunteer
[12], to fulfill personal roles, and to participate in social life
were common concerns [13]. Further research to under-
stand the impact of PsA and its treatment on patient work
productivity is therefore warranted.
At a PsA workshop held during the Outcome Measures
in Rheumatology (OMERACT) 7 meeting, participants
discussed domains that should be included in PsA clinical
trials, and generated a final list of aspects to be included,
which was presented and ratified; 61% of respondents in-
dicated that participation (in activities such as housework
and remunerative employment) should be included as a
domain, compared with 48% for fatigue and 91% for phys-
ical function [14]. The core set of domains, for inclusion
in all clinical trials of PsA, included joints, skin, patient’s
global assessment of disease activity, pain, function, and
health-related quality of life (HRQoL). The domain ofparticipation was considered potentially important but
still in need of research regarding its inclusion and how
to assess it [15].
In order to fully quantify the impact of an intervention
on patient productivity, it is crucial to consider the entire
patient productivity continuum both within the work and
home environments [16]. Historically, there has been an
unmet need for an instrument designed to assess presentee-
ism and absenteeism in both the workplace and household.
This has been highlighted in several reviews assessing the
properties of self-reported instruments measuring princi-
pally worker productivity [17-20].
The arthritis-specific Work Productivity Survey (WPS)
was developed to fulfill the unmet need for an arthritis-
specific instrument to assess the impact of an intervention
on patient productivity within the work and home envi-
ronments, in addition to daily activities during the preced-
ing month [21]. The WPS has demonstrated properties of
discriminative validity, reliability and responsiveness for
the measurement of patient productivity within and out-
side the home in patients with active RA [21].
There is no gold standard measure for assessing prod-
uctivity in PsA. During the OMERACT 9 meeting, based
on the available filter evidence (truth, discrimination and
feasibility) the WPS was one of six instruments identi-
fied by the OMERACT Worker Productivity Group as a
possible candidate for assessing worker productivity
changes in rheumatology [22].
The WPS was selected to estimate patient productivity
limitations associated with PsA because of the ease of use
and positive response, in terms of psychometric proper-
ties, seen in RA [21], and the similarity in terms of work
disability associated with RA and PsA.
The objective of this paper was to assess the discrim-
inant validity, responsiveness and reliability of the WPS
in adult-onset PsA.
Materials and methods
Patients and study design
The psychometric validation of the WPS was conducted
using data from the double-blind period of the RAPID-
PsA study (efficacy and safety of certolizumab pegol
(CZP) in PsA), which was double blind and placebo con-
trolled to week 24, dose blind to week 48 and then open
label to week 216 [23]. The first 24 weeks of the RAPID-
PsA study investigated CZP 200 mg every 2 weeks,
400 mg every 4 weeks or placebo, and was conducted at
92 sites across North America, Latin America, Western
Europe and Central/Eastern Europe from March 2010 to
November 2011. Institutional review boards or ethics
committees approved the protocol at each center (see
Additional file 1). All patients gave written informed
consent, and the study was conducted in accordance
with the Declaration of Helsinki [23].
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(saline) every 2 weeks or subcutaneous CZP 400 mg at
weeks 0, 2 and 4 (loading dose) followed by either CZP
200 mg every 2 weeks or CZP 400 mg every 4 weeks until
week 24 [23]. Placebo patients who failed to achieve a 10%
improvement from baseline in both swollen and tender
joints at weeks 14 and 16 were eligible for blinded
mandatory escape to active treatment. These patients were
re-randomized to active treatment at week 16 in a 1:1 ratio
(CZP 200 mg every 2 weeks:CZP 400 mg every 4 weeks),
receiving loading doses at weeks 16, 18 and 20. CZP pa-
tients continued to receive the initially assigned dose [23].
The primary efficacy endpoint was the American
College of Rheumatology 20% improvement criteria
(ACR20) response at week 12 [24,25]. Secondary end-
points included the American College of Rheumatology
50% improvement criteria (ACR50), the American College
of Rheumatology 70% improvement criteria (ACR70), Dis-
ease Activity Score – 28-joint count based on C-reactive
protein (DAS28(CRP)), physical functioning as measured
by the Health Assessment Questionnaire – Disability
Index (HAQ-DI) and the Psoriatic Arthritis Response Cri-
teria (PsARC), psoriatic skin involvement as measured by
the Psoriasis Area and Severity Index (PASI), HRQoL
assessed using the Short Form-36 health survey (SF-36),
EuroQoL-5 dimensions (EQ-5D), Psoriatic Arthritis Qual-
ity of Life (PsAQoL) and Dermatology Life Quality Index
(DLQI), and productivity measured using the WPS.
Questionnaires
The WPS is a disease-specific questionnaire assessing the
impact of arthritis on patient workplace and household
productivity and on daily activities during the preceding
month. The questionnaire is interviewer administered,
self-reported by the patient and has a 1-month recall
period [21]. Full details on its development have been re-
ported previously [21].
The first item of the WPS addresses current labor market
participation (‘are you currently employed outside the
home?’), which is a strong indicator of work ability since
not working implies complete loss of paid productivity.
Normative and comparative data on employment status are
also assessed. Two items capture self-reported absenteeism
(days of work missed) and presenteeism (days with patient
productivity reduced by at least one-half) due to arthritis,
and two items capture the same concepts but applied to
nonpaid (household) work. Additional items capture the re-
spondent’s estimate of the extent to which arthritis has in-
terfered with the patient’s work productivity (paid and
nonpaid) on a scale of 0 to 10 (0 = no interference and
10 = complete interference), the number of days in the last
month that outside help was hired because of arthritis, and
the number of days in the last month that family, social or
leisure activities were missed because of arthritis [21].The HAQ-DI is a patient-reported questionnaire that
provides an assessment of the impact of the disease on
ability to perform activities of daily living [26]. HAQ-DI
scores of 0 to 1 generally represent mild to moderate
functional difficulty, scores of 1 to 2 represent moderate
to severe functional difficulty, and scores of 2 to 3 indi-
cate severe to very severe limitations of physical func-
tion or disability [27]. In this study, the interpretation of
within-patient changes used for the HAQ-DI scores was
based on a minimum clinically important difference
(MCID) of 0.3 points [28]; this threshold was used to
define responders.
The DAS28(CRP) is a composite score measuring dis-
ease activity, with lower scores indicating lower disease
activity [29].
The PASI is a measure of severity of psoriatic skin in-
volvement [30,31]. The PASI ranges from 0 (no disease)
to 72 (maximal disease). The PASI75 response is based
on at least 75% improvement from baseline in the PASI
score. In RAPID-PsA, the PASI and PASI75 response
were assessed in the subgroup of patients with psoriasis
involving at least 3% of body surface area at baseline.
A PsARC response is defined as at least a 30% im-
provement of tender joint count or swollen joint count,
as well as a one-point improvement on a five-point scale
in the Patient’s Global Assessment of Disease Activity
and the Physician’s Global Assessment of Disease Activ-
ity, and no worsening of any of these scores [32].
The PsAQoL questionnaire was developed by McKenna
and colleagues as a quality-of-life measure specific to adult
patients with PsA [13]. The PsAQoL global score ranges
from 0 to 20, with a lower score indicating a better HRQoL.
The DLQI, developed in 1994, was the first dermatology-
specific quality-of-life instrument [33]. The DLQI score
ranges from 0 to 30, where higher scores represent greater
impairment on the quality of life.
The SF-36 is a widely used generic HRQoL instrument
that evaluates eight health domains: physical functioning,
role physical, bodily pain, general health, vitality, social
functioning, role emotional, and mental health [34]. The
eight domains are summarized in two component sum-
maries: the physical component summary (PCS) and the
mental component summary (MCS). Scores for the SF-36
range between 0 and 100, with higher scores indicating a
better HRQoL.
The EQ-5D questionnaire is comprised of a five-item
health status measure and a visual analog scale (VAS)
[35,36]. Each of the five dimensions is divided into three
levels – no problem, some or moderate problems, and ex-
treme problems – and is scored as 1, 2, and 3, respectively.
The EQ-5D VAS records the respondent’s self-rated health
status on a vertical 20 cm scale, graduated from 0 to 100
(0 =worst imaginable health status, 100 = best imaginable
health status).
Osterhaus and Purcaru Arthritis Research & Therapy 2014, 16:R140 Page 4 of 14
http://arthritis-research.com/content/16/4/R140The ACR20/ACR50/ACR70 response assesses the treat-
ment of symptoms and signs in patients with active PsA. A
patient is defined as an ACR20/ACR50/ACR70 responder
if there is an improvement (that is, reduction) of at least
20%/50%/70%, respectively, from baseline in the tender
joint count, swollen joint count and at least three of the five
core set measures: Patient’s Assessment of Arthritis Pain
(VAS), Patient’s Global Assessment of Disease Activity
(VAS), Physician’s Global Assessment of Disease Activity
(VAS), an acute-phase reactant (C-reactive protein), and
physical functioning based on the HAQ-DI [24].
Further details of the questionnaires assessed have
been included in Additional file 2.
Data handling and statistical analysis
The assessment of the psychometric properties (discrimin-
ant validity, responsiveness and reliability) of the WPS was
performed on the observed cases in the overall random-
ized set (RS) population (that is, all patients randomized
into the study), regardless of the randomization group.
Discriminant validity
Given the nature of the WPS questionnaire – which is
composed of several single–global questions scored and
interpreted separately – and the length of the recall
period of these questions, the construct validity of the
WPS questionnaire was evaluated by means of discrim-
inant validity, using correlations and the known-groups
validation method [37]. The association between the re-
sponses to WPS Questions 2 to 9 and scores of the dif-
ferent measures assessing the disease activity, physical
functioning or HRQoL was assessed through Kendall
correlation coefficients. Given the diverse nature of the
measures tested, and the current lack of or limited re-
search into patient productivity in PsA, a priori hypoth-
eses were made regarding the degree to which different
outcomes correlate with the WPS.
Given the difference between the concepts assessed by
the WPS questions and the other measures considered, the
a priori hypothesis tested was that the correlation coeffi-
cients are expected to be low to moderate (low, 0 to 0.3;
moderate, ≥0.3 to <0.5), thus indicating a divergent validity
of the measures compared [37]. High correlations could
imply a low discriminant validity and suggest that two
items are measuring similar concepts [37]. The Kendall as-
sociation coefficients were evaluated between WPS Ques-
tions 2 to 9 and the following selected measures: DAS28
(CRP), PASI (in patients with at least 3% body surface area
at baseline), HAQ-DI, SF-36 MCS, PCS and domains, PsA-
QoL, DLQI and EQ-5D VAS.
The known-groups validity method was used to com-
pare the patient productivity scores between patients
with a worse health state and patients with a better
health state. Patients with a higher disease activity, worseHRQoL or lower physical functioning were considered to
be in a worse health state, whereas patients with lower dis-
ease activity, better HRQoL or higher physical functioning
were considered to be in a better health state. The hypoth-
esis tested through the known-groups validity method was
that patients with a worse health state were expected
a priori to have higher losses in productivity at work out-
side home and within the household (that is, higher WPS
scores for Questions 2 to 9) due to their disease compared
with patients with a better health state. The known-
groups were formed using the first and third quartile
scores for each outcome as cutoff points. Patients were
considered to have better HRQoL if they had baseline SF-
36 scores ≥ third quartile or a PsAQoL or DLQI baseline
score ≤ first quartile, whereas those with SF-36 scores ≤
first quartile or PsAQoL or DLQI scores ≥ third quartile
were defined as having worse HRQoL. Similarly, better
physical functioning was defined as HAQ-DI ≤ first quar-
tile or SF-36 physical functioning domain (or PCS
scores) ≥ third quartile, with worse physical functioning
delineated by HAQ-DI ≥ third quartile and SF-36 ≤ first
quartile. Patients with DAS28(CRP) or PASI score ≤ first
quartile were considered to have low disease activity/se-
verity, whereas DAS28(CRP) or PASI score ≥ third quartile
indicated high disease activity/severity.
The discriminant validity of the WPS was assessed using
baseline observed data. To test the validity of patient
productivity at paid work (WPS Questions 2 to 4), cutoff
points were computed using only patients employed out-
side the home; whereas for productivity within the home
(Questions 5 to 9), the thresholds were computed using all
patients. Sensitivity analyses were performed using a me-
dian cutoff threshold.
A nonparametric bootstrap t method was used to
compare the mean WPS question responses between the
known-groups [38]. This method was favored because of
the highly skewed distribution of the WPS scores. Boot-
strap analyses were performed with 10,000 replications.
A variance-stabilizing transformation was used in order
to adjust for dependence between the bootstrap values
and the corresponding standard error.Responsiveness to clinical changes and reliability
The responsiveness of the WPS to clinical changes in a
patient’s condition over time was evaluated by compar-
ing the changes from baseline in productivity scores be-
tween clinical responders versus nonresponders at week
12 (as measured by ACR20). The hypothesis tested was
that clinical responders were expected a priori to have
higher improvements in productivity at work outside
home and within the household versus nonresponders,
reflected by higher negative changes (in absolute value)
in WPS scores.
Table 1 Baseline demographics and clinical characteristics
(randomized set, observed cases)
All randomized
patients (n = 409)
Demographic characteristics
Age (years) 47.6 ± 11.4
Sex (% female) 55.3
Race (% white) 97.8
Weight (kg) 84.4 ± 18.8
Body mass index (kg/m2) 29.8 ± 6.5
Arthritis characteristics
Time from psoriatic arthritis diagnosisa (years) 8.6 ± 8.2
C-reactive proteinb (mg/l) 8.0 (0.1 to 238.0)
Mean tender joint count (0 to 68 joints) 20.3 ± 14.9
Mean swollen joint count (0 to 66 joints) 10.7 ± 8.0
Physician’s Assessment of Disease Activity,
by VAS (mm)
57.9 ± 18.6
Patient’s Assessment of Disease Activity 59.1 ± 20.7
Patient’s Assessment of Arthritis Pain, by VAS (mm) 60.3 ± 20.4
DAS28 (CRP) 5.0 ± 1.0
Mean HAQ-DI (range 0 to 3) 1.31 ± 0.64
Psoriasis characteristics
Psoriasis BSA ≥3% (%) 61.6
PASIc 11.7 ± 11.9
Prior use of synthetic DMARDs (%) 50.6
1 47.2
≥2
Prior TNF inhibitor exposure (%) 19.6
Health-related quality of life
Mean SF-36 MCS 41.7 ± 12.1
Mean SF-36 PCS 33.4 ± 7.7
Mean PsAQoL 11.1 ± 5.6
Mean DLQI 8.5 ± 7.2
Mean EQ-5D VAS 49.9 ± 20.4
Data presented as mean ± SD, percentage or median (minimum to maximum).
BSA, body surface area; DAS28(CRP), Disease Activity Score – 28-joint count
based on C-reactive protein; DLQI, Dermatology Life Quality Index; DMARD,
disease-modifying antirheumatic drug; EQ-5D, EuroQoL-5 dimensions; HAQ-DI,
Health Assessment Questionnaire – Disability Index; MCS, mental component
summary; PASI, Psoriasis Area and Severity Index; PCS, physical component
summary; PsAQoL, Psoriatic Arthritis Quality of Life; SF-36, Short Form-36
items; TNF, tumor necrosis factor; VAS, visual analogue scale. aFrom the start
date of the primary disease. bNormal range < 8.0 mg/l. cPASI scores are
presented for patients with psoriasis body surface area ≥ 3% at baseline.
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ered a responder if they met the criteria of ACR20 im-
provement over baseline at week 12. Any patient who did
not meet the ACR20 or who withdrew from the study for
any reason before week 12 was considered a nonresponder.
The reliability of the WPS was tested in conjunction
with the responsiveness to the ACR20 clinical response
by comparing the changes in WPS scores in patients
achieving ACR50, ACR70, PASI75 (in patients with at
least 3% body surface area at baseline), HAQ-DI MCID,
PsARC and DAS28(CRP) remission (DAS28(CRP) < 2.6)
responses at week 12 versus nonresponders.
WPS score changes from baseline at week 12 were
compared between week 12 clinical responders and non-
responders using a nonparametric bootstrap t method.
A variance-stabilizing transformation was used in order
to adjust for dependence observed between bootstrap
values and the corresponding standard error. Bootstrap
analyses were performed with 10,000 replications.
In addition to the comparison of the changes in WPS
scores between the clinical responders and nonre-
sponders, the standardized response mean (SRM) was
calculated. The SRM is one of the most widely used
measures of the effect size of the response, indicating
whether the change was large relative to the variability
of the measurements. The SRM is estimated as the mean
change in scores between two visits divided by the
standard deviation of that change in scores. Thresholds
for the SRM (absolute values) were proposed by Cohen
and colleagues in order to interpret the size of the ef-
fects: small, from 0.2 to 0.5; moderate, from 0.5 to 0.8;
and large, >0.8 [39].
The responsiveness and reliability of the WPS was




A total of 409 patients were randomized and 368 (90%)
patients completed the 24-week phase.
Overall, RS patients had a mean age of approximately
48 years (range 19 to 75 years), slightly more than one-
half (55.3%) of the patients were female and almost all
patients were white (97.8%). The mean body mass index
overall was nearly 30 kg/m2, with 40.3% of patients hav-
ing body mass index ≥30 kg/m2 (Table 1).
The mean duration of PsA for all patients was 8.6 years,
and 80.0% of patients had disease duration of at least
2 years. Allowed disease-modifying antirheumatic drugs at
baseline and prior tumor necrosis factor inhibitor treat-
ment were equally distributed. Approximately 20% of pa-
tients had received previous treatment with tumor
necrosis factor inhibitors. The mean C-reactive protein for
all patients was 15.9 mg/l; small differences in mean C-reactive protein values across groups were not clinically
meaningful. The mean HAQ-DI and DAS28(CRP) scores
were similar across treatment groups (1.31 and 5.01 points
overall, respectively) and were indicative of moderate dis-
ease activity.
By geographic region, the largest percentage of patients
came from Central/Eastern Europe (47.9% overall).
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ment groups.
At baseline, 59.4% of all patients were employed outside
the home, 14% were unable to work due to PsA and 13.5%
were retired; the rest were homemakers (6.1%), unable to
work due to non-PsA health problems (3.4%), students
(1.2%) or had other unemployment status (2.2%) (Table 2).Baseline productivity within and outside the home
The burden of PsA at study baseline was high. Within the
workplace, the mean number of days of work missed was
2.0 over the previous month, while the mean number of
days per month with patient productivity reduced by at
least one-half was 4.7. The impact of PsA on household
productivity and participation in daily activities was even
higher than within the workplace (Table 3).
Patients in jobs with some manual component had a
similar number of workplace days missed per month to
those in exclusively nonmanual jobs (mean 2.1 vs.
2.0 days). However, these patients reported more days
per month with patient workplace productivity reduced
by at least one-half compared with those with exclusively
nonmanual jobs (mean 5.7 vs. 3.6 days respectively). Pa-
tient bias may play a part in these results, because it is
probable that patients with more severe PsA symptoms
would be less likely to take on manual roles. In terms of
household work, employed patients reported less impact
of PsA symptoms compared with nonemployed patients
and with patients unable to work due to arthritis (mean
household work days missed/month: 4.0 vs. 8.1 vs. 12.8;
mean days per month with household productivity re-
duced by ≥50%: 6.3 vs. 9.5 vs. 13.5, respectively).Table 2 Patient employment statusa at baseline
(randomized set, observed cases)
All randomized
patients (n = 409)
Employment status




Unable to work due to arthritis 57 (14.0)




Job function if employed
Nonmanual 111 (27.3)
Manual with no supervisory duties 89 (21.9)
Mixed (manual and nonmanual) 42 (10.3)
aCaptured through the Work Productivity Survey. Data presented as n (%).Completion rates of WPS at baseline
At baseline, all patients in the RS population answered
at least one of the WPS questions; there were no pa-
tients with a completely missing WPS questionnaire.
The completion rates of each of the WPS questions at
baseline in the RS population were very high, indicating
that the instrument was clear, acceptable and representa-
tive of the study population, and therefore that the re-
sults can be generalizable to a larger PsA population.
There were only three (0.7%) missing answers to WPS
Questions 5 to 9 at baseline. Among all employed RS pa-
tients at baseline who were required to answer WPS
Questions 2 to 4, the completion rates were also high,
with only one (0.4%) missing answer (for Question 4).
At baseline, there was no presence of a ceiling effect
as shown by the very small number of patients with a
maximal answer. In the RS population, three (1.2%) and
eight (3.3%) of the employed patients had an answer
≥30 days for WPS Question 2 and Question 3 respect-
ively, and nine (3.7%) had a maximum answer of 10 for
Question 4. Among all patients, 10 to 28 (2.5 to 6.9%)
patients had an answer ≥30 days for WPS Questions 5
to 8 or a maximal score of 10 for Question 9.
As expected, in terms of floor effect, the percentage of
patients with a minimal response varied between the dif-
ferent WPS questions, with a higher number of patients
answering 0 for Question 2 (work days missed in the
past month, 73.7% out of the employed RS population)
and for Question 8 (days with outside help hired, 77.3%
out of the entire RS population), and ranging from 14.3
to 57.6% for the other questions.
Discriminant validity
The first hypothesis – tested using the association coeffi-
cients between WPS Questions 2 to 9 and different con-
tinuous measures assessing the disease activity, physical
functioning and HRQoL – was confirmed. Coefficients
were low (<0.3) to moderate (≥0.3 to 0.5) as expected,
indicating divergent validity between the individual WPS
questions and the other measures considered (Table 4).
The level and the sign (positive or negative) of the
Kendall association coefficients indicated that better pa-
tient productivity at work and within home (that is, lower
answers to WPS Questions 2 to 9) was associated with
better HRQoL, better physical activity and lower disease
activity (Table 4). Although the association coefficients be-
tween patient productivity within and outside the home
and HRQoL were low to moderate, the association coeffi-
cients versus DLQI were very low, indicating that in-
creased patient productivity levels within and outside the
home were not associated with the DLQI level. Very low
positive or negative association coefficients were also ob-
served between PASI and the WPS questions, indicating
no association between these two measures (Table 4).
Table 3 Workplace and household productivity at baseline (randomized set, observed cases)
All randomized patients (n = 409)
WPS questiona n Mean (SD) Median
2. Number of days of work missed (absenteeism)b 243 2.0 (5.33) 0.0
3. Number of days with productivity ≤50% at work (presenteeism)b,c 243 4.7 (7.41) 0.0
4. Rate of arthritis interference with work productivityb,d 242 4.1 (2.83) 5.0
5. Number of days of household work missed 406 5.7 (8.41) 2.0
6. Number of days with productivity ≤50% in household workc 406 7.6 (8.67) 5.0
7. Number of days of family, social or leisure activities missed 406 3.7 (7.25) 0.0
8. Number of days with outside help 409 2.4 (6.43) 0.0
9. Rate of arthritis interference with household work productivityd 409 5.0 (2.95) 5.0
SD, standard deviation. aRecall period for Work Productivity Survey (WPS) is 1 month. bAssessed in employed patients only. cDays counted exclude those counted
in previous question. dScored using numeric rating scale of 0 to 10, where 0 = no interference and 10 = complete interference.
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known-groups analyses, was also confirmed, with results
indicating that there was a higher burden of arthritis on
patient productivity at both paid work and within the
home in patients with a worse health state versus pa-
tients with a better health state. Among employed pa-
tients in the RS population, patients with a worse health
state reported two to four times more work days lost,
more work days with patient productivity reduced by
one-half, and a higher interference of arthritis on work
productivity compared with patients with a better health
state (all P < 0.05 except for days with productivity re-
duced by 50% versus DAS28(CRP)) (Table 5).
At baseline, employed patients with a worse HRQoL,
assessed through the SF-36 MCS or PCS score, had lost
on average three times more full days of paid work per
month (mean 2.9 or 3.2 days respectively) compared with
patients with a better HRQoL (mean 0.3 or 0.9 days re-
spectively) (Table 5). In terms of days with reduced patient
productivity at work, employed patients with a worse
HRQoL as assessed by SF-36 MCS or PCS had a signifi-
cantly higher number of workdays with reduced patient
productivity (mean 7.2 and 6.9 days per month, respect-
ively) compared with patients with a better HRQoL (mean
3.0 and 2.5 days, respectively) (Table 5). Similar differences
were observed in patients with a worse versus better PsA-
specific HRQoL as assessed by PsAQoL (Table 5). Similar
significant differences were also observed when comparing
the rate of arthritis interference with patient work prod-
uctivity in employed patients with a better HRQoL com-
pared with patients with a worse HRQoL (Table 5).
Employed patients with worse physical functioning, as
assessed by HAQ-DI or SF-36 PCS score, had a signifi-
cantly higher number of work days lost and of days with
reduced patient productivity per month, as well as a
higher rate of arthritis interference with patient work
productivity when compared with patients with better
physical functioning (Table 5). Similarly, employed patients
with a lower disease activity, as assessed by a DAS28(CRP)score ≤ first quartile, had a significantly lower number of
work days lost per month, as well as a lower rate of arthritis
interference with patient work productivity when compared
with patients with higher disease activity (Table 5).
Similar patterns were observed when examining the dif-
ferences in household productivity, as assessed by the
WPS (Table 6). Compared with patients with a better
health state, patients with a worse health state reported on
average two to six times more days lost of household
work, more days with household productivity reduced by
at least one-half, more days missed of family, social or leis-
ure activities, more days with outside help hired and a
higher interference of arthritis per month (Table 6).
Compared with patients with a worse HRQoL, patients
with a better HRQoL (as assessed by SF-36 PCS, MCS and
PsAQoL) missed significantly fewer days of household work
(1.4 to 2.5 vs. 9.2 to 11.1 mean days per month, P <0.05),
had significantly fewer days with household work product-
ivity reduced by at least one-half due to arthritis (2.9 to 5.2
vs. 10.8 to 11.4 mean days), had lost a significantly lower
number of days of family, social or leisure activities (0.4 to
1.4 vs. 7.7 to 7.9 mean days) and had significantly fewer
days with outside help hired due to arthritis over the pre-
ceding month (0.1 to 0.6 vs. 4.7 to 5.3 mean days) (Table 6).
The rate of arthritis interference on household work prod-
uctivity reported by patients with a worse HRQoL was sig-
nificantly higher compared with patients with a better
HRQoL (on average 3.0 to 3.5 vs. 6.5 to 6.8 on a 0-point to
10-point scale) (Table 6). Significant differences were also
obtained when the known-groups were defined using the
SF-36 domains (data not shown).
Consistent findings were observed in patients with bet-
ter versus worse physical functioning as measured by the
HAQ-DI and SF-36 PCS, as well as in patients with a
lower versus higher disease activity (Table 6).
The known-groups analysis defined based on PASI were
inconclusive, as no consistent or significant differences
were seen for any of the WPS questions (Tables 5 and 6).
These findings are in line with the association analysis,
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a scale of 0 to 10
DAS28 (CRP) 0.16** 0.09 0.16** 0.22** 0.13** 0.15** 0.12* 0.24**
PASIa 0.11 0.06 −0.02 −0.01 0.05 0 0.02 −0.04
HAQ-DI 0.25** 0.21** 0.32** 0.34** 0.26** 0.28** 0.22** 0.38**
SF-36 MCS −0.16** −0.16** −0.22** −0.23** −0.24** −0.34** −0.24** −0.28**
SF-36 PCS −0.19** −0.15** −0.28** −0.31** −0.20** −0.19** −0.15** −0.32**
SF-36 PF −0.22** −0.16** −0.27** −0.36** −0.22** −0.25** −0.20** −0.34**
SF-36 BP −0.29** −0.20** −0.33** −0.34** −0.24** −0.33** −0.19** −0.38**
SF-36 RE −0.24** −0.21** −0.28** −0.29** −0.23** −0.35** −0.30** −0.31**
SF-36 RP −0.26** −0.24** −0.34** −0.32** −0.26** −0.28** −0.23** −0.37**
SF-36 GH −0.07 −0.09 −0.18** −0.16** −0.15** −0.15** −0.17** −0.20**
SF-36 MH −0.15* −0.15* −0.20** −0.19** −0.23** −0.29** −0.21** −0.27**
SF-36 SF −0.17** −0.21** −0.26** −0.30** −0.26** −0.36** −0.17** −0.30**
SF-36 VT −0.14* −0.10* −0.18** −0.27** −0.22** −0.27** −0.17** −0.30**
PsAQoL 0.24** 0.23** 0.30** 0.28** 0.28** 0.37** 0.27** 0.35**
DLQI 0.11# 0.03 0.06 0.08# 0.09* 0.15** 0.08# 0.10*
EQ-5D VAS −0.09 −0.09 −0.19** −0.15** −0.13** −0.14** −0.12** −0.20**
aAssessed only in patients with at least 3% body surface area at baseline. **P ≤ 0.001. *P ≤ 0.01. #P ≤ 0.05.
WPS Questions 2 to 4 were assessed in employed patients only, whereas Questions 5 to 9 were assessed in all patients; Questions 4 and 9 are 0 to 10 scales, where 0 = no interference and 10 = complete interference.
Correlation level (absolute value): low correlations, 0 to 0.1 (plain text), 0.1 (inclusive) to 0.3 (italic); moderate correlation, ≥0.3 to <0.5 (bold). HAQ-DI, lower score = better; DAS28, lower score = better; PASI, lower score =
better; PsAQoL, lower score = better; DLQI, lower score = better; SF-36, higher score = better; EQ-5D VAS, higher score = better. BP, bodily pain; DAS28(CRP), Disease Activity Score – 28-joint count based on C-reactive
protein; DLQI, Dermatology Life Quality Index; DMARD, disease-modifying antirheumatic drug; EQ-5D, EuroQoL-5 dimensions; GH, general health; HAQ-DI, Health Assessment Questionnaire – Disability Index; HRQoL,
health-related quality of life; MCS, mental component summary; MH, mental health; PASI, Psoriasis Area and Severity Index; PCS, physical component summary; PsAQoL, Psoriatic Arthritis Quality of Life; PF, physical

















Table 5 WPS baseline scores assessed by defined known-groups: patient workplace productivity (randomized set,
observed cases)
Instrumenta Number of days of work missed
over the previous month
Number of days with productivity ≤50%
at work over the previous month
Rate of arthritis interference with work
productivity over previous monthb
Worse Better Worse Better Worse Better
HAQ-DI 3.51* 0.99 6.77* 3.17 5.71** 3.00
(cutoff 0.75 and 1.50) n = 71 n = 78 n = 71 n = 78 n = 71 n = 78
DAS28(CRP) 3.54** 0.57 5.30 3.10 4.49# 3.18
(cutoff 4.13 and 5.64) n = 61 n = 61 n = 61 n = 61 n = 61 n = 61
SF-36 PCS 3.18* 0.87 6.85* 2.51 5.61** 2.69
(cutoff 29.56 and 40.43) n = 61 n = 61 n = 61 n = 61 n = 61 n = 61
SF-36 MCS 2.89** 0.33 7.20** 3.03 5.32** 3.15
(cutoff 35.77 and 52.45) n = 61 n = 61 n = 61 n = 61 n = 61 n = 61
PsAQoL 3.67** 0.47 8.11** 1.85 5.47** 2.71
(cutoff 6.00 and 15.00) n = 61 n = 78 n = 61 n = 78 n = 61 n = 78
PASI 2.79 1.33 4.49 3.25 3.67 3.78
(cutoff 3.60 and 14.40) n = 39 n = 40 n = 39 n = 40 n = 39 n = 40
Data presented as mean. DAS28(CRP), Disease Activity Score – 28-joint count based on C-reactive protein; HAQ-DI, Health Assessment Questionnaire – Disability
Index; MCS, mental component summary; PASI, Psoriasis Area and Severity Index; PCS, physical component summary; PsAQoL, Psoriatic Arthritis Quality of Life;
SF-36, Short Form-36 items; WPS, Work Productivity Survey. aCutoff points represent the first and third quartiles of baseline scores. Worse state defined for each
individual measure as: DAS28(CRP) score ≥ third quartile, HAQ-DI ≥ third quartile, PsAQoL ≥ third quartile, SF-36 MCS ≤ first quartile, SF-36 PCS ≤ first quartile, PASI ≥
third quartile. Better state defined for each individual measure as: DAS28(CRP) score ≤ first quartile, HAQ-DI ≤ first quartile, PsAQoL ≤ first quartile, SF-36 MCS ≥
third quartile, SF-36 PCS ≥ third quartile, PASI ≤ first quartile. bWPS Question 4 is a 0 to 10 scale, where 0 = no interference and 10 = complete interference.
**P ≤ 0.001. *P ≤ 0.01. #P ≤ 0.05. Nonparametric bootstrap t method with a variance stabilizing transformation, 10,000 replications.
Table 6 WPS baseline scores assessed by defined known-groups: household productivity and daily activities
(randomized set, observed cases)
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Worse Better Worse Better Worse Better Worse Better Worse Better
HAQ-DI 9.97** 1.60 11.97* 3.74 7.28** 1.43 4.82** 0.67 6.75** 3.22
(cutoff 0.88 and 1.75) n = 116 n = 116 n = 116 n = 116 n = 116 n = 116 n = 116 n = 116 n = 116 n = 116
DAS28 (CRP) 8.44** 2.70 9.26** 5.60 6.00** 1.58 3.68* 1.07 6.11** 3.70
(cutoff 4.23 and 5.73) n = 103 n = 101 n = 103 n = 101 n = 103 n = 101 n = 103 n = 101 n = 103 n = 101
SF-36 PCS 11.09** 1.37 10.81** 4.22 7.74** 1.37 4.65** 0.63 6.54** 3.30
(cutoff 27.99 and 38.28) n = 101 n = 98 n = 101 n = 98 n = 101 n = 98 n = 101 n = 98 n = 101 n = 98
SF-36 MCS 10.10** 2.50 11.25** 5.19 7.91** 0.40 5.34** 0.18 6.65** 3.54
(cutoff 32.76 and 50.78) n = 100 n = 101 n = 100 n = 101 n = 100 n = 101 n = 100 n = 101 n = 100 n = 101
PsAQoL 9.16** 1.70 11.44** 2.94 7.74** 0.35 4.97** 0.12 6.75** 3.04
(cutoff 6.00 and 16.00) n = 104 n = 103 n = 104 n = 103 n = 104 n = 103 n = 104 n = 103 n = 104 n = 103
PASI 4.69 6.21 8.18 5.68 3.08 4.35 1.81 2.21 4.40 4.89
(cutoff 3.70 and 15.50) n = 62 n = 66 n = 62 n = 66 n = 62 n = 66 n = 62 n = 66 n = 62 n = 66
Data presented as mean. DAS28(CRP), Disease Activity Score – 28-joint count based on C-reactive protein; HAQ-DI, Health Assessment Questionnaire – Disability
Index; MCS, mental component summary; PASI, Psoriasis Area and Severity Index; PCS, physical component summary; PsAQoL, Psoriatic Arthritis Quality of Life;
SF-36, Short Form-36 items; WPS, Work Productivity Survey. aCutoff points represent the first and third quartiles of baseline scores. Worse state defined for each
individual measure as: DAS28(CRP) score ≥ third quartile, HAQ-DI ≥ third quartile, PsAQoL ≥ third quartile, SF-36 MCS ≤ first quartile, SF-36 PCS ≤ first quartile, PASI ≥
third quartile. Better state defined for each individual measure as: DAS28(CRP) score ≤ first quartile, HAQ-DI ≤ first quartile, PsAQoL ≤ first quartile, SF-36 MCS ≥
third quartile, SF-36 PCS ≥ third quartile, PASI ≤ first quartile. bWPS Question 4 is a 0 to 10 scale, where 0 = no interference and 10 = complete interference.
**P ≤ 0.001. *P ≤ 0.01. #P ≤ 0.05. Nonparametric bootstrap t method with a variance stabilizing transformation, 10,000 replications.
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PASI and WPS questions did not indicate that the skin
index is associated with productivity scores within or out-
side the home.
Sensitivity analyses using median cutoff values (see
Additional file 3) demonstrated similar trends, with pa-
tients in worse health states reporting poorer worker
productivity outcomes compared with patients in better
health states. Slight numerical differences of the sensitiv-
ity analysis compared with the base analysis may be due
to the fact that patients within the outlying quartiles are
likely to have more extreme health states.Responsiveness and reliability
WPS changes from baseline by ACR20 response at week 12
The responsiveness hypothesis was confirmed, with sig-
nificantly greater improvements in household and patient
workplace productivity observed in ACR20 responders
versus nonresponders at week 12 (except in work days
missed (WPS Question 2) and days with outside help
(WPS Question 8), where only numerical differences were
seen) (Figure 1).
The effect sizes of the changes in productivity scores,
measured by the SRM, were negligible (SRM< 0.1) or
small (SRM< 0.5) in ACR20 nonresponders; whereas
moderate effect sizes were observed in ACR20 responders
(or small in the case of days missed at work (WPS Ques-
tion 2), days missed of family/social/leisure activities
(WPS Question 7) and days with outside help hired (WPS
Question 8)) (Figure 2a).Figure 1 Mean changes from baseline in the Work Productivity Surve
criteria clinical response at week 12. Change from baseline in the Work
improvement criteria (ACR20) clinical response at week 12 (randomized set
nonresponders; P-values were obtained using the nonparametric bootstrap
(0 = no interference and 10 = complete interference). WP, work productivityWPS changes from baseline by other response measures at
week 12
With regards to the reliability hypothesis, differences
observed in HAQ-DI MCID and ACR50 responders
versus nonresponders were similar and consistent with
those reported for ACR20. When assessing the respon-
siveness of WPS to more stringent clinical responses,
like ACR50, the effect sizes in mean changes in patient
productivity within and outside the home in the ACR50
responder group were moderate to large (or small in the
case of days missed at work (WPS Question 2), days
missed of family/social/leisure activities (WPS Question
7) and days with outside help hired (WPS Question 8))
(Figure 2b). Effect sizes observed when assessing the
WPS responsiveness in HAQ-DI MCID responders ver-
sus nonresponders were also similar to those observed
for ACR20 (Figure 2c). For the PsARC response, the ef-
fect sizes in mean changes in patient productivity scores
were low in all WPS questions except Question 4 (rate
of interference with work productivity) and Question 9
(rate of interference with household work productivity),
where the effect sizes were moderate.
The results based on the ACR70 and Disease Activity
Score – 28-joint count remission criteria were incon-
clusive due to a large imbalance in the sample sizes of
the two groups compared. Although the effect sizes of
the mean changes in WPS responses compared with
the PASI75 response were small to moderate, there
were no statistically significant differences in changes
in productivity scores between PASI75 responders and
nonresponders.y by American College of Rheumatology 20% improvement
Productivity Survey by American College of Rheumatology 20%
, observed cases). **P≤ 0.001, *P < 0.01 responders versus
t method. Rate of interference is a score on a scale of 0 to 10 points
.
Figure 2 Effect size of mean changes from baseline in the Work Productivity Survey at week 12 (randomized set, observed cases).
Effect size (standardized response mean (SRM)) of mean changes from baseline in the Work Productivity Survey (WPS) are presented by the
(a) American College of Rheumatology 20% improvement criteria (ACR20) clinical response, (b) American College of Rheumatology 50%
improvement criteria (ACR50) clinical response, and (c) Health Assessment Questionnaire – Disability Index (HAQ-DI) minimal clinically important
difference (MCID of 0.3) clinical response. SRM (absolute values) thresholds: small, from 0.2 to 0.5 (below the dashed line); moderate, from 0.5 to
0.8 (between the two lines); and large, >0.8 (above the solid line).
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The disease-specific WPS is a tool developed to estimate
patient productivity limitations due to arthritis in the
workplace and in household activities [21], whose psycho-
metric properties have already been demonstrated in sub-
jects with active RA [21]. Previous work demonstratedthat the WPS could efficiently evaluate both the burden of
the disease and clinical interventions on work outcomes
in patients with RA [21,40,41].
The objective of this paper was to evaluate the initial
psychometric properties of WPS in an adult-onset PsA
population. The discriminant validity, the responsiveness
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therefore evaluated in subjects enrolled in a clinical trial
for the treatment of active PsA.
OMERACT 6 and OMERACT 7 have highlighted the
importance to patients of considering the impact of
arthritic conditions on paid and unpaid work outcomes
[42,43], as they represent an important component of
the health and wellbeing of rheumatology patients. Simi-
lar thinking should apply to patients with PsA. Patient-
reported outcomes have been included in rheumatology
trials because they capture the patient’s perspective of
the disease process and the impact of treatments on the
disease. The impact of PsA on work outcomes is not
currently a core component of rheumatology clinical tri-
als; however, it is an endpoint of interest to both patients
and employers. OMERACT has re-enforced the import-
ance of work productivity as an outcome measure in
rheumatology through the Worker Productivity Special
Interest Group, which has reviewed specific productivity
instruments and continues to evaluate concepts and
methodological and interpretation issues surrounding
work productivity [44].
The findings indicated that the WPS instrument was
generally well understood by patients, as indicated by the
high completion rates. As in RA, the WPS demonstrated
good discriminant validity both in terms of association co-
efficients and known-groups analyses evaluated against a
range of different continuous measures assessing disease
activity (DAS28(CRP)), physical functioning (HAQ-DI,
SF-36 PCS and SF-36 physical functioning), and HRQoL
(SF-36, PsAQoL, EQ-5D). The Kendall association coeffi-
cients indicated the divergent validity between the individ-
ual WPS questions and these measures, which were
further confirmed by the known-groups analyses. Com-
pared with patients in a better health state, patients in a
worse health state had on average two to six times greater
patient productivity losses due to PsA within the house-
hold. Similar findings were observed among employed pa-
tients, with patients in a worse health state reporting on
average two to four times greater patient productivity
losses within the workplace compared with patients with a
better health state.
The known-groups were constructed using the first and
third quartiles of the instrument scores at baseline in
order to avoid comparison of unbalanced groups [21].
These analyses were further confirmed using a median
cutoff of the score (see Additional file 3). The responsive-
ness of the WPS was assessed using clinically recognized
thresholds, and supports the discriminant validity analysis.
The WPS was responsive to clinical changes, as mea-
sured by the ACR20 response. Clinical responders at
week 12 had significantly larger improvements in patient
productivity within and outside the home and in daily
activities compared with nonresponders. Similar findingswere observed when using a different clinical response
(for example, HAQ-DI MCID, ACR50), supporting the
responsiveness and the reliability of the WPS. The ob-
served differences in WPS score changes and the effect
sizes seen for clinical responders and nonresponders,
and the similarities in the responsiveness of the WPS
questions when using different response criteria, support
the responsiveness and reliability of the WPS in patients
with PsA.
WPS was not found to be associated with the skin-
related measures DLQI and PASI response. This may in-
dicate that these aspects of disease have relatively little
impact on the productivity of patients with PsA.
Among all WPS questions, the work days missed due
to PsA and the days with outside help hired did show a
certain level of responsiveness, but not as large or con-
sistent as the other WPS questions. The number of re-
spondents who reported full days missed or days with
outside help hired was quite small relative to the entire
study sample. This suggests that in this sample PsA in-
terfered with patient work productivity, but was less
likely to lead to full disability. This also suggests that
PsA patients might not necessarily hire outside help, but
does not exclude the possibility of receiving help from
relatives or friends. Given the utility of WPS across a
variety of rheumatic conditions, including those where
higher levels of disability would be anticipated, all ques-
tions of the WPS should remain, ensuring an accurate
assessment of the impact of arthritis on different aspects
of patient work and household productivity.
The limitations of this study included the patient
population, which was recruited for a clinical trial of ac-
tive PsA and may not be completely representative of
the wider PsA population. However, as the WPS is cur-
rently developed as a tool for clinical trials, the patient
population used should provide sufficient evidence to
ensure the validity of this measure in its current role.
The WPS is also affected by the normal limitations of
self-reported questionnaires, although previous reports
have confirmed that self-reporting is still the best means
of collecting this type of data [45].
In the absence of a gold standard to measure patient
work productivity in randomized clinical trials, the cri-
terion validity of the WPS could not been assessed. In-
stead, another type of validity (that is, discriminant) has
been evaluated in the current paper. A cross-cultural
validation of the WPS has not yet been assessed, given
the objective and quantitative nature of the WPS. Work
to further support the use of this questionnaire to assess
workplace and household productivity is ongoing.
Conclusions
The present analysis is the first report on the psycho-
metric properties of the WPS in PsA, demonstrating its
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be used to capture the impact of active PsA on patient
productivity in the workplace and within the household,
and participation in daily activities. It is also a credible
instrument for use in clinical trials and in clinical prac-
tice to assess the impact of treatment on PsA-related
patient workplace and household productivity losses.
Additional files
Additional file 1: is a table presenting a list of ethical bodies
approving the RAPID-PsA study.
Additional file 2: is a table presenting details of the questionnaires
assessed in the article.
Additional file 3: is Tables S1 and S2 presenting WPS baseline
scores assessed by defined known-groups. Known-groups analysis
using median scores as the cutoff for analysis.
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